Midazolam B. Braun (Midazolam Hydrochloride)

Midazolam enhances the activity of the neurotransmitter GABA at the GABA‑A receptor. By increasing chloride ion flow into neurons, it hyperpolarizes the cell membrane, reducing neuronal firing and producing sedation, anxiolysis, muscle relaxation, and anticonvulsant effects.

The specific dose of Midazolam B. Braun is determined by the prescribing clinician based on the patient’s age, weight, clinical condition, and the intended procedure. Dosing guidelines are provided in the product’s prescribing information and should be individualized for each patient.

Midazolam’s pregnancy category is not definitively established. It should be used during pregnancy or lactation only when the potential benefits justify the potential risks to the fetus or infant. Clinicians must evaluate each case carefully and consider alternative therapies when possible.

To order Midazolam B. Braun, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Midazolam has a rapid onset and short duration compared with longer‑acting benzodiazepines such as diazepam. This makes it preferable for brief procedures and induction of anesthesia, whereas agents like diazepam are often chosen for longer‑lasting anxiolysis or seizure prophylaxis.

Midazolam should be stored at controlled room temperature, below 25 °C, in its original packaging. Protect the vial from light, moisture, and extreme temperature fluctuations. Once reconstituted, use according to the manufacturer’s stability guidelines and discard any unused portion after the recommended time.

Midazolam can be administered intravenously, intramuscularly, or rectally, depending on the clinical situation. Intravenous injection provides the fastest onset, while intramuscular or rectal routes are used when IV access is not immediately available or for specific procedural needs.

The most serious risks include severe respiratory depression, paradoxical agitation or aggression, cardiac arrhythmias, and anaphylactic reactions. Continuous monitoring of respiratory and cardiovascular status is essential, especially when higher doses or concurrent depressant drugs are used.

Midazolam is contraindicated in patients with known hypersensitivity to benzodiazepines, severe respiratory insufficiency, acute narrow‑angle glaucoma, and in individuals who have had a recent severe allergic reaction to the product. Caution is also advised for patients with significant hepatic impairment or those taking interacting medications.